Directory of Stock Market Company
This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.
Search into NYSE and TSX
by quote, company name or key word
ARIA - Ariad Pharmaceuticals Inc
ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company focused on the discovery and development of drugs to provide therapeutic intervention in treating human diseases at the cellular level. As of December 31, 2010, the Company’s pipeline of product candidates included three compounds, such as ridaforolimus, ponatinib and AP26113. Its lead cancer product ca","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"
Ariad Pharmaceuticals Inc News
Top Healthcare Sector Buys And Sells In Billionaire Steven Cohen's Q1 Filing
Seeking Alpha - 3 hours ago
Seeking Alpha - 3 hours ago
Stamford, CT-based leading multi-strategy hedge fund SAC Capital, founded and led by legendary manager Steven Cohen, filed its latest 13-F for Q1 2012 indicating that it ended the quarter with $22.24 billion in 13-F assets, up from the $15.8 billion in ...
Here's What Smart Billionaire George Soros Is Buying andSelling - In Spotlight
The Mumbai Times - 4 hours ago
The Mumbai Times - 4 hours ago
The 13 analysts offering 12-month price forecasts for JDS Uniphase Corp have a median target of 16.00, with a high estimate of 18.00 and a low estimate of 14.00.
Discovery Laboratories: A Hidden Gem In Biotech
Seeking Alpha - May 21, 2012
Seeking Alpha - May 21, 2012
Investing in biotech companies can be viewed as "risky business" in today's world, with the FDA having a tight grip over the regulations needed for a product to reach the market.
Ariad Pharmaceuticals, ArQule, Exelixis, Aveo, Other Cancer Drug Stocks Fall
Minyanville.com - May 18, 2012
Minyanville.com - May 18, 2012
By Brett Chase May 17, 2012 20:00 pm Stocks for a number of cancer drug developers are falling Thursday as investors sift through scientific papers released ahead of a major medical conference next month.
Biotech-Focused Baker Bros. $3.7B Fund Bought These 3 Big Winners And Sold ...
Seeking Alpha - May 17, 2012
Seeking Alpha - May 17, 2012
New York-based Hedge Fund Baker Bros. Advisors LLC, as of the most recent SEC 13-F Q1 filing, had $3.7 billion in equity assets, almost all invested in the biotech sector, and an increase from the $3.0 billion in Q4 and $2.3 billion in Q3 of 2011.
Ariad Pharmaceuticals - Daily Volume Review
AVAFIN - May 16, 2012
AVAFIN - May 16, 2012
NEW YORK (AVAFIN) -- Block trades help investors understand the sentiment of large financial institutions. A total of 12 block trades were executed during the last trading session, typically at least 10000 shares or more represent a single block unit.
Ariad Announces Updated Findings from Pivotal Pace Trial of Ponatinib to Be ...
MarketWatch (press release) - May 16, 2012
MarketWatch (press release) - May 16, 2012
CAMBRIDGE, Mass., May 16, 2012 (BUSINESS WIRE) -- --~ Company to Host Investor Meeting and Webcast with Dr. Jorge Cortes on Monday, June 4 at 12pm (CT) ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that updated clinical data from the ...
Medivation, Ariad Pharmaceuticals Among Stocks Setting 52-Week Highs Wednesday
Fox Business - May 16, 2012
Fox Business - May 16, 2012
The share price of Medivation (MDVN) went up today, reaching and then surpassing its previous 52-week high of $88.51. In spite of its performance and peak price of $88.73, the stock was trading on below-average volume.
ARNA, VRTX, FE, ARIA, NEE Hit New 52-Week Highs
Fyxnews - May 16, 2012
Fyxnews - May 16, 2012
Arena Pharmaceuticals (NASDAQ:ARNA) hit a new 52 week high of $6.88 in intraday trading and closed at $6.61 +3.93% on 25941804 shares traded.
DHI, DFG, LEN, AMLN, DF Hit New 52-Week Highs - The Mumbai Times
Summer Street Raises Price Target on Ariad Pharmaceutical (ARIA)
Daily Political - May 15, 2012
Daily Political - May 15, 2012
Research analysts at Summer Street boosted their target price on shares of Ariad Pharmaceutical (NASDAQ: ARIA) to $21.00 in a report released on Monday.
Summer Street Research Boosts Price Target on Ariad Pharmaceutical (ARIA) - Movie News Guide (blog) NYSE Media Coverage Selection of the best articles found in your favorit medias